Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration Results From the IRIS Registry and Komodo Healthcare Map-论文-万方医学网

首页> > Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration Results From the IRIS Registry and Komodo Healthcare Map

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration Results From the IRIS Registry and Komodo Healthcare Map

导出原文传递

翻译打印收藏纠错

第一作者： Khanani, Arshad M.

作者： Khanani, Arshad M. ^[1] ; Zarbin, Marco A. ^[2] ; Barakat, Mark R. ^[3] ; Albini, Thomas A. ^[4] ; Kaiser, Peter K. ^[5] ; Guruprasad, B. ^[6] ; Agashivala, Neetu ^[7] ; Yu, Justin S. ^[8] ; Wykoff, Charles C. ; MacCumber, Mathew W.

作者单位： Rutgers New Jersey Med Sch,Rutgers State Univ ^[1] Retinal Consultants Arizona ^[2] Bascom Palmer Eye Inst ^[3] Cleveland Clin ^[4] Sierra Eye Associates ^[5] Novartis Pharmaceut ^[6] Retina Consultants Texas ^[7] Med Ctr,Rush Univ ^[8]

关键词 REAL-WORLD EFFICACY RELAPSE

发布时间 2022-09-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration Results From the IRIS Registry and Komodo Healthcare Map

相似文献

同项目论文

相关期刊

检索历史 清除

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration Results From the IRIS Registry and Komodo Healthcare Map

相似文献

同项目论文

相关期刊

检索历史清除